Tirzepatide + Placebo
ApprovedRecruiting 2 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type II Diabetes
Conditions
Type II Diabetes, Atherosclerosis
Trial Timeline
Jan 2, 2024 → May 1, 2026
NCT ID
NCT05708859About Tirzepatide + Placebo
Tirzepatide + Placebo is a approved stage product being developed by Eli Lilly for Type II Diabetes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05708859. Target conditions include Type II Diabetes, Atherosclerosis.
What happened to similar drugs?
20 of 20 similar drugs in Type II Diabetes were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06962280 | Phase 3 | Active |
| NCT06914895 | Phase 3 | Active |
| NCT06191848 | Approved | Recruiting |
| NCT06439277 | Phase 3 | Recruiting |
| NCT05708859 | Approved | Recruiting |
| NCT06075667 | Phase 3 | Active |
| NCT06037252 | Phase 2 | Active |
| NCT06047548 | Phase 3 | Active |
| NCT05963022 | Phase 3 | Completed |
| NCT05536804 | Phase 2 | Active |
| NCT05696847 | Phase 1 | Completed |
| NCT05691712 | Phase 3 | Completed |
| NCT05556512 | Phase 3 | Active |
| NCT05412004 | Phase 3 | Completed |
| NCT05024032 | Phase 3 | Completed |
| NCT04235959 | Phase 1 | Completed |
| NCT04081337 | Phase 1 | Completed |
| NCT04050553 | Phase 1 | Completed |
| NCT04184622 | Phase 3 | Completed |
| NCT04166773 | Phase 2 | Completed |
Competing Products
20 competing products in Type II Diabetes